An innovative CAR-T therapy with promising results – NCIS

National University Cancer Institute, Singapore (NCIS) shared on LinkedIn:

“Our doctors have developed an innovative CAR-T therapy with promising results! This new treatment was administered in a trial involving patients who have exhausted standard treatment pathways for T-cell Actute Lymphoblastic Leukemia (T-ALL), in which 16 of them went into full remission within a month. This innovative therapy works by modfying the patient’s own T-cells to identify and target CD7 receptors on the cancer cells.

At NCIS, every person matters. We are the only public institution in Singapore that treats both adult and paediatric cancer. Our doctors are not only committed in the treatment of patients, but also in developing innovative therapies that greatly improves their chances of survival.

Find out more about this new therapy here!

Alternativly, for our readers who would like to dive into the science of it – the results have also been published in Nature Medicine! Have a look with the following link.

The CD7 CAR-T team comprises of:

Dr Bernice Oh
Consultant, Division of Paediatric Haematology and Oncology, Department of Paediatrics, Khoo Teck Puat National University Children’s Medical Institute, National University Hospital

Prof Allen Yeoh
Head and Senior Consultant, Division of Paediatric Haematology and Oncology, Department of Paediatrics, Khoo Teck Puat National University Children’s Medical Institute, National University Hospital

Dr Esther Chan
Senior Consultant, Division of Haematology, Department of Haematology-Oncology, National University Cancer Institute, Singapore.”

Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia

Authors: Bernice L.Z. Oh,Natasha Vinanica,Desmond M.H. Wong,Dario Campana

Source: National University Cancer Institute, Singapore/LinkedIn